BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37316446)

  • 1. [Correlation Analysis between Thyroid Function Abnormality and Efficacy in Patients 
with Advanced Non-small Cell Lung Cancer after Immunotherapy].
    Wang Y; Wang X; Cheng L; Zhang G
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):369-376. PubMed ID: 37316446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors.
    Zhong X; Ying J; Liao H; Shen L; Pan Y
    Future Oncol; 2022 Jun; 18(18):2289-2300. PubMed ID: 35440175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
    Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
    J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive Value of LIPI and iSEND Immune Scoring System 
in Immunotherapy of Advanced Non-small Cell Lung Cancer].
    Luo Y; Wang X; Wang Y; Zhang G
    Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):803-810. PubMed ID: 36419394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
    Lobefaro R; Viscardi G; Di Liello R; Massa G; Iacovino ML; Sparano F; Della Corte CM; Ferrara R; Signorelli D; Proto C; Prelaj A; Galli G; De Toma A; Brambilla M; Ganzinelli M; Trevisan B; Ciardiello F; De Braud F; Morgillo F; Garassino MC; Lo Russo G
    Lung Cancer; 2021 Feb; 152():165-173. PubMed ID: 33421923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
    Liu Y; Zhang T; Gao Y; Qu Y; Lu B; Zhang H; Wang Q; Li J; Hu F; Li B
    Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):687-695. PubMed ID: 31771737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
    Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
    Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
    Front Immunol; 2020; 11():1173. PubMed ID: 32587591
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
    Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
    Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitors treatment failure].
    Wang C; Li Y; Guan Y; Yang SJ; Yin JC; Zhang CF; Guo QS; Shi WN
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(16):1210-1216. PubMed ID: 37087404
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
    Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis.
    Qin J; Yi S; Zhou H; Zeng C; Zou M; Zeng X; Yang Z; Huang Y
    Front Immunol; 2023; 14():1138025. PubMed ID: 37261356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
    Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peripheral Blood Inflammation Indicators as Predictive Indicators in 
Immunotherapy of Advanced Non-small Cell Lung Cancer].
    Xia J; Chen Y; Wen S; Du X; Shen B
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.